Skip to content
INDEPENDENT BUSINESS INTELLIGENCE Checks every minute · Checked 03:10:47 GMT+0000
MARKETS Delayed
NIFTY 50 25,291.10 +0.58%
SENSEX 82,104.79 +0.63%
S&P 500 7,416.59 -1.92%
NASDAQ 24,509.76 -2.49%
BTC/USD $64,573.95 -0.74%
ETH/USD $1,817.35 -0.47%
BRENT $91.70 -0.80%
GOLD $3,870.20 +0.45%

GLOBAL BUSINESS & MARKETS

Global Business Research article

FDA rejects Summit’s ivonescimab; shares drop 19.9% premarket

The FDA rejected Summit Therapeutics' lung cancer drug ivonescimab over survival data, sending Summit shares down 19.9% premarket. What it means.

Published 5 min read
Prepared bydeepak
Editorial statusSources reviewed
Linked sources6
How we verify →
AI Audio Reader

AI-assisted research analysis by FutureKnowledge. Sources checked 16 November 2026. This is not investment advice.

Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.

Summit Therapeutics shares fell 19.9% to $11.33 in US premarket trading on Monday after the FDA rejected its lung cancer drug ivonescimab, Reuters reported. The regulator issued a complete response letter on Sunday, 15 November, turning down the first US application for a drug from the closely watched PD-1 x VEGF bispecific antibody class.

The decision matters beyond one company. Ivonescimab was developed in China by Akeso and licensed to Summit, and it has been treated as a test case for Chinese-origin drugs reaching Western markets. Several of the world’s largest drugmakers are also developing drugs that work in a similar way.

What happened: the FDA’s ivonescimab decision

Summit had asked the FDA to approve ivonescimab with platinum-based chemotherapy for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations, whose disease had progressed after EGFR tyrosine kinase inhibitor therapy. The application rested on the global Phase III HARMONi trial, according to Summit’s press release filed with the SEC.

According to Summit’s account of the letter, the FDA said substantial evidence of effectiveness was not established without a statistically significant improvement in overall survival. The agency added that a progression-free survival (PFS) benefit on its own does not support a positive benefit-risk profile for approval in this setting.

HARMONi met its PFS primary endpoint. On overall survival, the primary analysis showed a positive trend but did not reach statistical significance. Summit said a later, post-hoc analysis with longer follow-up showed an overall survival hazard ratio of 0.76, consistent across the full population, Asian patients and Western patients. The company noted that no FDA-approved regimen in this setting has shown a statistically significant survival benefit. Reports differ on the size of the PFS gain: Investing.com cited a 48% reduction in the risk of progression or death, while The Motley Fool cited 43%. Summit’s release does not give the figure.

On safety, Summit reported treatment-related discontinuations of 7.3% in the ivonescimab arm against 5.0% for placebo plus chemotherapy, and treatment-related deaths of 1.8% against 2.3%, with no new safety signals.

Why the FDA said no

The core issue is the FDA’s standard of evidence. In many cancers, a delay in tumour progression can support approval, but the agency has increasingly asked for proof that patients live longer, especially when a new drug adds side effects to an existing regimen. TD Cowen analysts told Reuters the decision was consistent with “the high bar the agency had previously set”.

Summit had argued that its post-hoc survival data showed the benefit held among Western patients as well as Asian ones. That matters because Seoul Economic Daily, citing earlier reporting, noted that the drug’s early evidence came largely from China, where it was first approved in May 2024. The FDA did not accept post-hoc analyses as a substitute for a pre-specified, statistically significant survival result.

What the Summit Therapeutics rejection means for business

For Summit, the setback removes its nearest route to US revenue. Summit acquired rights to ivonescimab for the US, Canada, Europe and Japan from Akeso in 2022 in a deal that Reuters and Investing.com describe as valued at up to $5 billion. Akeso keeps China and other markets, where the drug is already sold. Summit’s release says over 100,000 patients have been treated commercially in China.

For the wider drug class, BMO Capital’s Evan Seigerman told Reuters the decision sets a meaningful regulatory precedent. Reuters listed Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie as companies with similar candidates. The likely read-across is that trial designs will need to target overall survival, which means larger and longer studies. Pfizer, which raised its 2026 revenue outlook earlier this month, is among the companies named.

For China’s biotech out-licensing model, the decision is a reminder that approval in China and strong regional data do not guarantee US approval. It comes as US-China commercial ties are already under strain; see our coverage of the extension of China’s tariff pause on US goods. Summit still points to five positive Phase III studies between Summit and Akeso, and the larger commercial prize, first-line lung cancer, is untouched by this letter.

Who is more or less exposed

  • More exposed: companies whose value depends on one late-stage asset in a class now facing a higher evidence bar, and licensors whose milestone payments are tied to US approvals.
  • Moderately exposed: large drugmakers with PD-1 x VEGF programmes, whose trials may need survival endpoints and longer timelines; diversified portfolios dilute the effect.
  • Less exposed: companies with established immunotherapies such as PD-1 drugs already on the market, where a slower arrival of new rivals may extend their position.

Scenarios to watch

The table below sets out conditional scenarios, not predictions.

If this happens Possible consequence
First-line lung cancer trial (HARMONi-3) shows a statistically significant survival benefit The class case would be largely restored, and the current rejection would look like a narrow setback in one setting.
HARMONi-3 shows PFS gains but no clear survival benefit FDA scrutiny of the class would likely intensify, affecting rival programmes and licensing valuations.
Summit seeks a resubmission with mature survival data A longer timeline to any US launch; financing needs would come into focus.
Rivals redesign trials around overall survival Higher development costs and later launches across the class.

What to watch next

  • Whether Summit sets out a path with the FDA. Its release gives no resubmission plan or meeting date.
  • HARMONi-3 in first-line NSCLC. Reuters said analysts are watching a late-stage first-line readout expected later this year; Summit has not given a date.
  • Akeso’s response in Hong Kong and any comments on milestone timing.
  • Read-across in trial design and statements from other PD-1 x VEGF developers.

Bottom line

The FDA’s rejection of ivonescimab is about evidence standards more than safety: the agency wants a statistically significant survival benefit, not just slower tumour growth, in previously treated EGFR-mutant lung cancer. Summit shares fell sharply, but the larger test for the drug and its class is the first-line lung cancer data still to come.

Method note: This analysis compared Summit Therapeutics’ 15 November 2026 press release (via SEC EDGAR and Summit’s investor site) with reporting from Reuters, Investing.com, The Motley Fool and Seoul Economic Daily. Where reports differed on the premarket share fall and the PFS figure, we used Reuters for the share price and flagged the PFS difference.

Sources & further reading

  1. sec.govArchives/edgar/data/1599298/000159929826000092/ivonescimabcrlscenariopr.htm
  2. smmttx.comnews/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
  3. 933thedrive.com2026/11/16/summit-shares-drop-after-us-fda-declines-to-approve-lung-cancer-drug
  4. investing.comnews/stock-market-news/summit-therapeutics-stock-plunges-after-fda-rejects-lung-cancer-drug-5028928
  5. fool.cominvesting/breakfast-news/2026/11/16/breakfast-news
  6. en.sedaily.comworld/2026/11/16/fda-rejects-china-developed-lung-cancer-drug-denting
WhatsAppXLinkedIn